Paola P Grandi

US Patent:

20190262410, Aug 29, 2019

Filed:

Nov 14, 2018

Appl. No.:

16/191141

Inventors:

- Pittsburgh PA, US
Justus B. Cohen - Allison Park PA, US
Paola Grandi - Pittsburgh PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 35/763
C07K 14/005
C12N 7/00

Abstract:

The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

US Patent:

20170274025, Sep 28, 2017

Filed:

Jun 7, 2017

Appl. No.:

15/616585

Inventors:

- Pittsburgh PA, US
Justus B. Cohen - Allison Park PA, US
Paola Grandi - Pittsburgh PA, US

International Classification:

A61K 35/763
C07K 14/005
C12N 7/00

Abstract:

The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

US Patent:

20170035819, Feb 9, 2017

Filed:

Jul 7, 2016

Appl. No.:

15/204350

Inventors:

- Pittsburgh PA, US
Justus B. Cohen - Allison Park PA, US
Paola Grandi - Pittsburgh PA, US

International Classification:

A61K 35/763
C12N 7/00

Abstract:

The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

US Patent:

20160250267, Sep 1, 2016

Filed:

Oct 28, 2014

Appl. No.:

15/032958

Inventors:

- Pittsburgh PA, US
Justus B. COHEN - Allison Park PA, US
Paola GRANDI - Pittsburgh PA, US

International Classification:

A61K 35/763
C12N 7/00

Abstract:

The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.